单剂鼻内亚单位疫苗快速清除高剂量肺鼠疫感染继发性脓毒症
研究开发了将鼠疫耶尔森菌毒力因子LcrV和F1偶联至烟草花叶病毒(TMV)的亚单位疫苗,单剂鼻内接种可保护88%小鼠抵抗100 LD50鼠疫耶尔森菌CO92pgm-致死攻击,而rF1+rV无保护作用。TMV-F1/V免疫小鼠组织病理、细菌负荷和炎性细胞因子显著降低,仅该组小鼠能快速清除脾和肝内细菌,攻击前血清F1滴度与恢复直接相关。
要点
- 单剂鼻内TMV-F1/V疫苗对高剂量肺鼠疫攻击提供88%保护。
- 无TMV佐剂的rF1+rV疫苗无保护作用。
- 攻击前血清F1抗体滴度与免疫小鼠恢复直接相关。
核心结论
- 单剂鼻内TMV-F1/V亚单位疫苗无需额外佐剂即可有效保护小鼠免受致死性肺鼠疫感染。
研究设计与样本
- 小鼠模型研究:比较TMV-F1/V单剂鼻内免疫与rF1+rV免疫及未免疫组,攻击后不同时间点采集血清和组织。
主要发现
- TMV-F1/V免疫组88%小鼠抵抗100 LD50鼠疫耶尔森菌CO92pgm-攻击,rF1+rV组无保护。
- TMV-F1/V组组织病理、细菌负荷和炎性细胞因子产生较rF1+rV组和未免疫组显著降低。
- 肺攻击后所有组均发生细菌全身播散,但仅TMV-F1/V组小鼠快速清除脾和肝内细菌。
- 攻击前血清F1滴度与所有免疫小鼠的恢复直接相关。
关键数值与推荐
- 单剂鼻内TMV-F1/V保护88%小鼠抵抗100 LD50鼠疫耶尔森菌CO92pgm-攻击。
- rF1+rV无TMV时对同剂量攻击无保护作用。
临床怎么用
- 提示鼻内单剂TMV偶联亚单位疫苗可作为抗耐药鼠疫的候选黏膜免疫策略。
- 血清F1抗体滴度可能作为评估疫苗保护效果的免疫 correlate。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yersinia pestis, the causative agent of plague, has killed millions throughout human history. Though public health initiatives have reduced the number of plague cases, it remains endemic in many areas of the world. It also remains a significant threat for use as a biological weapon. Naturally occurring multi-drug antibiotic resistance has been observed in Y. pestis, and resistant strains have been engineered for use as a biological weapon. Vaccines represent our best means of protection against the threat of antibiotic resistant plague. We have developed a vaccine consisting of two Y. pestis virulence factors, LcrV (V) and F1, conjugated to Tobacco Mosaic Virus (TMV), a safe, non-replicating plant virus that can be administered mucosally, providing complete protection against pneumonic plague, the deadliest form of the disease and the one most likely to be seen in a biological attack. A single intranasal (i.n.) dose of TMV-F1 + TMV-V (TMV-F1/V) protected 88% of mice against lethal challenge with 100 LD50 of Y. pestis CO92pgm-, while immunization with rF1 + rV without TMV was not protective. Serum and tissues were collected at various timepoints after challenge to assess bacterial clearance, histopathology, cytokine production, and antibody production. Overall, TMV-F1/V immunized mice showed a significant reduction in histopathology, bacterial burden, and inflammatory cytokine production following challenge compared to rF1 + rV vaccinated and unvaccinated mice. Pneumonic challenge resulted in systemic dissemination of the bacteria in all groups, but only TMV-F1/V immunized mice rapidly cleared bacteria from the spleen and liver. There was a direct correlation between pre-challenge serum F1 titers and recovery in all immunized mice, strongly suggesting a role for antibody in the neutralization and/or opsonization of Y. pestis in this model. Mucosal administration of a single dose of a Y. pestis TMV-based subunit vaccine, without any additional adjuvant, can effectively protect mice from lethal infection.
引用
- D'Arco C, McCormick AA, Arnaboldi PM, et al. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection. Vaccine. 2021. PMID: 33531196. doi:10.1016/j.vaccine.2021.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。